TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00756509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 800 mg/d orally
Study: NCT03987022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Use of non-steroidal anti-inflammatory drug for pain control postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: Use of narcotic for pain control postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Use of narcotic for pain control postoperatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Packs
Description: Placement of Ice packs on surgical sites postoperatively
Study: NCT01545414

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICONTROL
Description: 12 weeks of Internet-based treatment with a focus on relaxation training
Study: NCT01596192

Intervention type: OTHER
Intervention: PETCT
Description: CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec.
Study: NCT01807091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive outpatient induction chemotherapy
Study: NCT02667015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy (Anxiety Sensitivity Intervention)
Description: 3 week, 6-session psychotherapy targeting anxiety sensitivity
Study: NCT06442306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
Study: NCT01051323

Intervention type: DRUG
Intervention: methoxy polyethylene glycol-ep [Mircera]
Description: As prescribed by physician
Study: NCT02460367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tergenpumatucel-L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Study: NCT03219619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap-EGD
Description: Undergoing cap-assisted endoscopy
Study: NCT03916120

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Collect 2ml intravenous blood from patients after anaesthesia.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Collect 2ml intravenous blood from patients after anaesthesia.
Study: NCT01386827

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mouse brain derived japanese encephalitis vaccine (MB-JEV)
Description: a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml \> 2 years later

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary and booster immunizations with MB-JEV
Description: 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml \> 2 years later

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C) primary immunizations with Ixiaro
Description: 2 0.5 ml doses of Ixiaro 28 days apart
Study: NCT03219619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duo
Description: Undergoing side-viewing duodenoscope
Study: NCT03987022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Use of pain medication postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin
Description: Use of non-steroidal anti-inflammatory drug for pain control postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid Injectable Product
Description: Use of narcotic for pain control postoperatively
Study: NCT01386827

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: S) Ixiaro booster to MBJEV primed
Description: 0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
Study: NCT03470441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Study: NCT04645576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face correction with injectable fillers
Description: Injection of hyaluronic acid-based fillers
Study: NCT03470441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Study: NCT04482881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate 40 MG
Description: giving women isosorbide mononitrate 40 MG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate 60 MG
Description: giving women isosorbide mononitrate 60MG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Giving women misoprostol
Study: NCT01564381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ResA
Description: 90mg of resveratrol conjugated with arginine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 90mg of resveratrol.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made up of cellulose.
Study: NCT03005314

Intervention type: PROCEDURE
Group type: OTHER
Intervention: chemotherapy
Description: chemotherapy before surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: chemotherapy after surgery
Study: NCT02052050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability
Study: NCT04669847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk-oriented exercise program
Description: The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program
Description: Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program
Description: Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
Study: NCT03987022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilaudid Injectable Product
Description: Use of narcotic for pain control postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 5Mg-325Mg Tablet
Description: Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
Study: NCT04013542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04645576

Intervention type: DEVICE
Group type: OTHER
Intervention: Face correction with injectable fillers
Description: Injection of hyaluronic acid-based fillers

Intervention type: DEVICE
Group type: OTHER
Intervention: Face correction with injectable fillers
Description: Injection of hyaluronic acid-based fillers

Intervention type: DEVICE
Group type: OTHER
Intervention: Face correction with injectable fillers
Description: Injection of hyaluronic acid-based fillers
Study: NCT01711580

Intervention type: OTHER
Intervention: EORTC QLQ-C30
Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.

Intervention type: OTHER
Intervention: EORTC QLQ-BN20
Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.

Intervention type: OTHER
Intervention: Hopkins Verbal Learning Test-Revised (HVLT-R)
Description: The HVLT-R is a cognitive test to assess verbal learning and memory.

Intervention type: OTHER
Intervention: Stroop color-word test
Description: The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.

Intervention type: OTHER
Intervention: Controlled oral word association test (COWA)
Description: The COWA is a measure of verbal fluency that requires expressive language and executive functions.

Intervention type: OTHER
Intervention: Jamar hand dynamometer
Description: The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.

Intervention type: OTHER
Intervention: EORTC QLQ- FA13
Description: The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30

Intervention type: OTHER
Intervention: Trail Making Test (TMT)
Description: The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
Study: NCT04263493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation (physiotheraphy)
Description: Time of loading, range of motion exercises, strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation (physiotheraphy)
Description: Time of loading, range of motion exercises, strength training
Study: NCT03944304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
Study: NCT03538990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Eating Pattern
Description: The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
Study: NCT00195624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath )
Description: Campath administered at a dose of 10/mg/day for 10 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath )
Description: Campath administered at a dose of 10/mg/day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
Study: NCT02685618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips M1006B, offset by -10mmHg
Description: Administration of blood pressure module M1006B: offset by -10 mmHg

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phillips M1006B, offset by -10mmHg
Description: Administration of blood pressure module M1006B: offset by -10 mmHg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips M1006B, No offset
Description: Administration of blood pressure module M1006B: No offset

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Philips M1006B, No offset
Description: Administration of blood pressure module M1006B: No offset
Study: NCT05882123

Intervention type: OTHER
Intervention: cerebral microbleeds
Description: Whether patients with acute ischemic stroke are complicated by cerebral microbleeds

Intervention type: OTHER
Intervention: cerebral microbleeds
Description: Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
Study: NCT02044406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181
Description: single dose (low to high dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181, R
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181, T2
Description: tablet, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1181181
Description: Placebo to BI 1181181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181, T1
Description: tablet, fed
Study: NCT01609738

Intervention type: DEVICE
Intervention: Left ventricular septum pacing lead
Description: A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.

Intervention type: DEVICE
Intervention: Left ventricular septum pacing lead
Description: A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
Study: NCT02114489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: Unique perfusion of ibandronate 3 mg IV
Study: NCT03558698

Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2

Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2

Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2

Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2

Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2

Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents

Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents

Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents

Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents

Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents

Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents
Study: NCT02114489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01152411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells
Description: Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
Study: NCT02725268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 capsules.
Study: NCT00735527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Intra-nasal 0.1 mg/kg (maximum 4 mg) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Intra-venous 0.1 mg/kg (maximum 4 mg) once
Study: NCT02963766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study: NCT04220567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Exercise and Patient-centred education
Description: An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Exercise
Description: An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
Study: NCT03362489

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IVF / IVF-ICSI
Description: In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IUI
Description: In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department.